January 11, 2022 - … denies nearly all Medicare beneficiaries from accessing ADUHELM® (aducanumab-avwa) 100 mg/mL injection for … approval was supported by clinical data showing that ADUHELM impacted the underlying pathology of Alzheimer’s … screening for its post-marketing confirmatory study for ADUHELM® (aducanumab-avwa) in May 2022, with a primary …